رسالة جامعية
Therapeutic targeting of PRMT5 and mutant ACVR1 in paediatric glioma
العنوان: | Therapeutic targeting of PRMT5 and mutant ACVR1 in paediatric glioma |
---|---|
المؤلفون: | Brown, Elizabeth |
المساهمون: | Bullock, Alexander, Farnie, Gillian |
بيانات النشر: | University of Oxford, 2021. |
سنة النشر: | 2021 |
المجموعة: | University of Oxford |
مصطلحات موضوعية: | Brain, Central nervous system, Intracranial tumors in children, Cancer in children, Intracranial tumors, Tumors in children, Cancer cells, Cancer, Gliomas |
الوصف: | Diffuse Intrinsic Pontine Glioma (DIPG) is a universally fatal paediatric brainstem tumour with a median overall survival of 9-11 months. The unique genetic, anatomical and developmental identity of the tumour means that there are currently no effective chemotherapies or targeted therapies. This thesis aimed to identify and characterise novel targets for the treatment of DIPG. Potential therapeutic opportunities arise from the frequent mutations found in histone H3 (H3K27M) and kinase ACVR1 found in DIPG tumours. A screen of epigenetic protein inhibitors revealed that the viability of the patient-derived DIPG cell line HSJD-DIPG-007 was highly sensitive to arginine methyltransferase (PRMT) inhibitors, particularly in ACVR1 mutant lines. The PRMT5 inhibitor LLY-283 was identified as the most promising lead for its potent inhibition of DIPG viability and the recognised role of PRMT5 in the regulation of the cell cycle and stemness. RNA-sequencing and phenotypic analyses revealed that LLY-283 did not induce cell death, but reduced stemness and invasiveness, altered metabolism and restored H3K27me3 levels in DIPG cells. Through collaboration with Ángel Montero Carcaboso, LLY-283 was tested in an orthotopic murine xenograft model of DIPG. LLY-283 reduced infiltration of DIPG cells into the murine forebrain, but did not prolong survival, perhaps reflecting inadequate drug exposure. In parallel, the CRISPR/Cas9 system was used to correct the causative G328V ACVR1 mutation in DIPG cells. The resultant isogenic DIPG cells demonstrated slowed proliferation after correction of ACVR1 mutations, rather than a complete growth arrest as observed with published shRNA mediated ACVR1 knockdown. Surprisingly, the isogenic cell lines also showed comparable sensitivity (GI50) to PRMT5 and ACVR1 inhibition, suggesting other genetic differences contribute to the variation in treatment sensitivity between DIPG cell lines. My findings highlight the value of isogenic DIPG cell lines for interrogating the effects of individual tumorigenic mutations. It remains incredibly challenging to develop new strategies to treat DIPG. This thesis supports the future design of combination treatments for DIPG and provides new experimental tools to aid their development. |
نوع الوثيقة: | Electronic Thesis or Dissertation |
اللغة: | English |
الوصول الحر: | https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.860106Test |
رقم الانضمام: | edsble.860106 |
قاعدة البيانات: | British Library EThOS |
ResultId |
1 |
---|---|
Header |
edsble British Library EThOS edsble.860106 1007 3 Dissertation/ Thesis dissertation 1006.82037353516 |
PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsble&AN=edsble.860106&custid=s6537998&authtype=sso |
FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.860106 [Name] => EDS - British Library EThOS [Category] => fullText [Text] => View record in EThOS [MouseOverText] => View record in EThOS ) ) |
Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Therapeutic targeting of PRMT5 and mutant ACVR1 in paediatric glioma
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Brown%2C+Elizabeth%22">Brown, Elizabeth</searchLink> ) Array ( [Name] => Author [Label] => Contributors [Group] => Au [Data] => Bullock, Alexander<br />Farnie, Gillian ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => University of Oxford, 2021. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2021 ) Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => University of Oxford ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Brain%22">Brain</searchLink><br /><searchLink fieldCode="DE" term="%22Central+nervous+system%22">Central nervous system</searchLink><br /><searchLink fieldCode="DE" term="%22Intracranial+tumors+in+children%22">Intracranial tumors in children</searchLink><br /><searchLink fieldCode="DE" term="%22Cancer+in+children%22">Cancer in children</searchLink><br /><searchLink fieldCode="DE" term="%22Intracranial+tumors%22">Intracranial tumors</searchLink><br /><searchLink fieldCode="DE" term="%22Tumors+in+children%22">Tumors in children</searchLink><br /><searchLink fieldCode="DE" term="%22Cancer+cells%22">Cancer cells</searchLink><br /><searchLink fieldCode="DE" term="%22Cancer%22">Cancer</searchLink><br /><searchLink fieldCode="DE" term="%22Gliomas%22">Gliomas</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Diffuse Intrinsic Pontine Glioma (DIPG) is a universally fatal paediatric brainstem tumour with a median overall survival of 9-11 months. The unique genetic, anatomical and developmental identity of the tumour means that there are currently no effective chemotherapies or targeted therapies. This thesis aimed to identify and characterise novel targets for the treatment of DIPG. Potential therapeutic opportunities arise from the frequent mutations found in histone H3 (H3K27M) and kinase ACVR1 found in DIPG tumours. A screen of epigenetic protein inhibitors revealed that the viability of the patient-derived DIPG cell line HSJD-DIPG-007 was highly sensitive to arginine methyltransferase (PRMT) inhibitors, particularly in ACVR1 mutant lines. The PRMT5 inhibitor LLY-283 was identified as the most promising lead for its potent inhibition of DIPG viability and the recognised role of PRMT5 in the regulation of the cell cycle and stemness. RNA-sequencing and phenotypic analyses revealed that LLY-283 did not induce cell death, but reduced stemness and invasiveness, altered metabolism and restored H3K27me3 levels in DIPG cells. Through collaboration with Ángel Montero Carcaboso, LLY-283 was tested in an orthotopic murine xenograft model of DIPG. LLY-283 reduced infiltration of DIPG cells into the murine forebrain, but did not prolong survival, perhaps reflecting inadequate drug exposure. In parallel, the CRISPR/Cas9 system was used to correct the causative G328V ACVR1 mutation in DIPG cells. The resultant isogenic DIPG cells demonstrated slowed proliferation after correction of ACVR1 mutations, rather than a complete growth arrest as observed with published shRNA mediated ACVR1 knockdown. Surprisingly, the isogenic cell lines also showed comparable sensitivity (GI50) to PRMT5 and ACVR1 inhibition, suggesting other genetic differences contribute to the variation in treatment sensitivity between DIPG cell lines. My findings highlight the value of isogenic DIPG cell lines for interrogating the effects of individual tumorigenic mutations. It remains incredibly challenging to develop new strategies to treat DIPG. This thesis supports the future design of combination treatments for DIPG and provides new experimental tools to aid their development. ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => Electronic Thesis or Dissertation ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.860106" linkWindow="_blank">https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.860106</link> ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsble.860106 ) |
RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Brain
[Type] => general
)
[1] => Array
(
[SubjectFull] => Central nervous system
[Type] => general
)
[2] => Array
(
[SubjectFull] => Intracranial tumors in children
[Type] => general
)
[3] => Array
(
[SubjectFull] => Cancer in children
[Type] => general
)
[4] => Array
(
[SubjectFull] => Intracranial tumors
[Type] => general
)
[5] => Array
(
[SubjectFull] => Tumors in children
[Type] => general
)
[6] => Array
(
[SubjectFull] => Cancer cells
[Type] => general
)
[7] => Array
(
[SubjectFull] => Cancer
[Type] => general
)
[8] => Array
(
[SubjectFull] => Gliomas
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Therapeutic targeting of PRMT5 and mutant ACVR1 in paediatric glioma
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Brown, Elizabeth
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Bullock, Alexander
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Farnie, Gillian
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Type] => published
[Y] => 2021
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-locals
[Value] => edsble
)
)
)
)
)
)
)
|
IllustrationInfo |